SCHEMBL5481528

SCHEMBL5481528

CS(=O)(=O)NCc1ccc(Oc2ccc3c(c2)S(O)(O)NCN3CCBr)cc1

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GRIA2 P42262 9/20 0.39
CNR2 P34972 1/20 0.36
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
KMT2A Q03164 1/20 0.33
SCN9A Q15858 1/20 0.33
POLB P06746 1/20 0.32
LMNA P02545 3/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5479901 0.91 GRIA2 (0.39) GRIA2CNR2SLC6A2SLC6A4SLC6A3
SCHEMBL5479955 0.91 GRIA2 (0.39) GRIA2CNR2SLC6A2SLC6A4SLC6A3
SCHEMBL5481531 0.90 GRIA2 (0.48) GRIA2CNR2SLC6A2SLC6A4SLC6A3
SCHEMBL5477040 0.83 GRIA2 (0.39) GRIA2KMT2APOLBSMN1; SMN2
SCHEMBL5479896 0.80 GRIA2 (0.48) GRIA2CNR2SLC6A2SLC6A4SLC6A3
SCHEMBL5479962 0.80 GRIA2 (0.52) GRIA2CNR2SLC6A2SLC6A4SLC6A3
SCHEMBL5482709 0.77 LTA4H (0.41) GRIA2SLC6A2SLC6A4SLC6A3LMNA
SCHEMBL5482327 0.75 GRIA2 (0.39) GRIA2
SCHEMBL1980618 0.74 CNR2 (0.39) CNR2SLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL5485316 0.73 GRIA2 (0.37) GRIA2LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1655030-B1 Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same SERVIER LAB (FR) 2007-12-19 EP disclosed
US-20070270415-A1 Benzothiadiazine compounds LESLABORATOIRES SERVIER (FR) 2007-11-22 US disclosed
US-7268130-B2 Benzothiadiazine compounds LES LABORATOIRES SERVIER (FR) 2007-09-11 US disclosed
EP-1655030-A1 Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same Les Laboratoires Servier (FR) 2006-05-10 EP disclosed
EP-1655030-A1 Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same Les Laboratoires Servier (FR) 2006-05-10 EP disclosed
US-20060094712-A1 New benzothiadiazine compounds LES LABORATOIRES SERVIER (FR) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270415-A1 Benzothiadiazine compounds SLC1A1, SLC1A2, SULT2A1 GRIA2 47/4885CNR2 464/4885SLC6A2 199/4885
US-20060094712-A1 New benzothiadiazine compounds SLC1A1, SLC1A2, GABRA5 GRIA2 36/4885CNR2 237/4885SLC6A2 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.